HM 21001

Drug Profile

HM 21001

Alternative Names: HM21001

Latest Information Update: 05 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ajou University School of Medicine
  • Developer Hanmi Pharmaceutical
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioblastoma

Most Recent Events

  • 14 Dec 2016 Ajou University transfers stem-cell based therapy to Hanmi Pharmaceutical for Glioblastoma
  • 14 Dec 2016 Hanmi Pharmaceuticals plans clinical development for Glioblastoma in 2017
  • 05 Dec 2016 Preclinical trials in Glioblastoma in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top